H.C. Wainwright lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $11 from $12 and keeps a Buy rating on the shares following the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics’ Earnings Call: Mixed Sentiment and Future Outlook
- Y-mAbs Therapeutics price target lowered to $20 from $21 at Oppenheimer
- Positive Outlook for Y-Mabs Therapeutics Amid Strategic Developments and NCCN Inclusion
- Y-mAbs Therapeutics Reports Q1 2025 Financial Results
- Cautious Outlook on Y-Mabs Therapeutics Amidst Competitive and Enrollment Challenges